Zacks: Analysts Set $3.00 Target Price for AEterna Zentaris Inc. (AEZS)

Shares of AEterna Zentaris Inc. (NASDAQ:AEZS) (TSE:AEZ) have been given a consensus broker rating score of 1.00 (Strong Buy) from the one analysts that cover the company, Zacks Investment Research reports. One research analyst has rated the stock with a strong buy rating.

Brokerages have set a one year consensus price objective of $3.00 for the company and are predicting that the company will post ($0.25) earnings per share for the current quarter, according to Zacks. Zacks has also assigned AEterna Zentaris an industry rank of 98 out of 257 based on the ratings given to its competitors.

A number of research firms have issued reports on AEZS. ValuEngine cut shares of AEterna Zentaris from a “hold” rating to a “sell” rating in a research report on Friday, August 10th. Zacks Investment Research upgraded shares of AEterna Zentaris from a “hold” rating to a “buy” rating and set a $1.75 price objective on the stock in a research report on Tuesday, October 9th.

NASDAQ AEZS traded up $0.13 on Monday, hitting $2.26. 253,654 shares of the company’s stock traded hands, compared to its average volume of 1,186,818. AEterna Zentaris has a 1-year low of $1.12 and a 1-year high of $3.25. The stock has a market cap of $33.87 million, a price-to-earnings ratio of -1.67 and a beta of 0.75.

AEterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) last announced its quarterly earnings data on Tuesday, November 6th. The biopharmaceutical company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.25) by $0.10. AEterna Zentaris had a net margin of 34.40% and a return on equity of 83.33%. The business had revenue of $0.66 million during the quarter. Sell-side analysts forecast that AEterna Zentaris will post 0.05 earnings per share for the current fiscal year.

AEterna Zentaris Company Profile

Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing pharmaceutical therapies for treating oncology, endocrinology, and women's health. Its commercial product is the Macrilen, a ghrelin receptor agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a, a ghrelin receptor, which is used for endocrinology and oncology indications.

Further Reading: Hedge Funds Explained

Get a free copy of the Zacks research report on AEterna Zentaris (AEZS)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for AEterna Zentaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AEterna Zentaris and related companies with's FREE daily email newsletter.

Leave a Reply